Medical Marketing & MediaOpinion

BIO campaign reiterates what’s at stake if biotech funding slips

The Fight of Our Lives highlights biotech’s impact on patient lives in both the short- and long-term, urging continued ...

Big pharma is thinking small on deals. That’s a boon for biotech.

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Biotech Stocks and Longevity Investing: Trends To Track

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
BioSpace

Biotech IPOs Rebound as AI Takes a More Central Role in Drug Development

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
Hosted on MSN

Biotech stocks are coming back. Here’s what’s driving the sector higher.

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 by 9 percentage ...
Opinion

America's biotech leadership depends on the states

For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments.
Morningstar

Biotech stocks are coming back. Here's what's driving the sector higher.

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...